Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Patients With Systemic Sclerosis

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: January 25, 2008
Last updated: March 17, 2017
Last verified: March 2017
This study will investigate the efficacy and safety of STI571 for the treatment of fibrosis in patients with systemic sclerosis. Other purposes of the study are to investigate whether STI571 is effective in improving lung functions and other test results called biomarkers. Whether STI571 is well-absorbed in systemic sclerosis patients' gut will also be investigated by testing the drug level in the blood (pharmacokinetics).

Condition Intervention Phase
Systemic Sclerosis, Scleroderma
Drug: STI571
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Multi-centre, Open-label, Proof of Concept (PoC) Study to Evaluate the Efficacy and Tolerability of STI571 for the Treatment of Fibrosis in Patients With Systemic Sclerosis

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Percentage change from baseline in modified Rodnan Skin Score (MRSS) at each time point of analysis [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • Assessment of non-response, partial response, complete response, remission or relapse assessed by MRSS values. [ Time Frame: 48 weeks ]

Enrollment: 27
Study Start Date: January 2008
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: STI571
STI571 tablets taken orally once a day
Other Name: Gleevec, Glivec


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female patients who are equal to or older than 18 years of age and who have early diffuse systemic sclerosis (Disease duration < 18 months from the first non-Raynaud's symptom)
  • Patients with a modified Rodnans Skin Score (MRSS) of at least 20 in the absence of trunk involvement or a MRSS of at least 16 in patients with trunk involvement
  • Practicing two acceptable forms of contraception

Exclusion Criteria:

  • Concurrent connective tissue diseases other than systemic sclerosis
  • Significant pre-existing heart, liver, lungs, digestive system, blood and other diseases, cancer
  • Conditions that might mimic the potential side effects of STI571 (blood conditions, liver damage, chronic diarrhea, edema)
  • Concurrent medical therapies (or during last 6 weeks before first dosing) that may potentially influence outcome of the study
  • allergic to the study medication
  • Pregnancy
  • Breast feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00613171

United States, Illinois
Novartis Investigator Site
Chicago, Illinois, United States, 60611
United States, Maryland
Novartis Investigator Site
Baltimore, Maryland, United States, 21224
United States, Massachusetts
Novartis Investigator Site
Boston, Massachusetts, United States, 02118
Novartis Investigator Site
Erlangen, Germany
Novartis Investigator Site
Florence, Italy
Novartis Investigator Site
Zurich, Switzerland
United Kingdom
Novartis Investigator Site
London, United Kingdom
Sponsors and Collaborators
Novartis Pharmaceuticals
Principal Investigator: NOVARTIS Novartis investigator site
  More Information

Additional Information:
Responsible Party: Novartis Pharmaceuticals Identifier: NCT00613171     History of Changes
Other Study ID Numbers: CSTI571E2205
Study First Received: January 25, 2008
Last Updated: March 17, 2017

Keywords provided by Novartis:
Systemic sclerosis, scleroderma, fibrosis, STI571, imatinib

Additional relevant MeSH terms:
Scleroderma, Systemic
Scleroderma, Diffuse
Pathologic Processes
Connective Tissue Diseases
Skin Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017